Product News: The Liposome Company
Executive Summary
The Liposome Company: Sales of Abelcet in the U.S. and overseas have exceeded $6 mil. so far in 1996, Princeton, N.J.-based firm says. "The launch of Abelcet has been extremely well received by physicians in the U.S." with "about 80% of the 50 hospitals that are the largest users of amphotericin B" buying the liposomal amphotericin formulation since its mid-December launch, TLC maintains. The company released the figures because it "is concerned about inaccurate information in the investment community concerning Abelcet and its sales prospects"...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth